Fig. 2

Bacterial 16S rRNA-based analysis of the fecal microbiota of WT and Gpr43^−/− mice. a Community composition bar plot of the fecal microbiota of naive WT B6 (B6 WT, n = 3) mice and naive Gpr43^−/− mice (GPCR43^−/−, n = 3), WT B6 mice 14 days after allo-BMT (allo-B6 WT, n = 4), Gpr43^−/− mice 14 days after allo-BMT (allo-GPCR43^−/−, n = 5), WT B6 mice 28 days after co-housing with Gpr43^−/− mice (Cohouse B6 WT, n = 6), Gpr43^−/− mice 28 days after co-housing with WT B6 mice (Cohouse GPCR43^−/−, n = 6), antibiotic-treated WT B6 mice 14 days after allo-BMT (ABX allo-B6 WT, n = 8) and antibiotic-treated Gpr43^−/− mice 14 days after allo-BMT (ABX allo-GPCR43, n = 9). b Principle coordinates analysis (PCoA) of distances between communities of the fecal microbiota of six Cohouse B6 WT and six Cohouse GPCR43^−/−, P = 0.199 by analysis of molecular variance (AMOVA). c, d WT B6 and Gpr43^−/− (single- or co-housed for 28 days before BMT) mice received BMT from either syngeneic allogeneic donors. Survival and clinical GVHD score after BMT (n = 3 each syngeneic, n = 12 allo SH WTB6, n = 17 allo CH WTB6, n = 14 allo CH Gpr43^−/−, n = 14 allo SH Gpr43^−/−, log-rank test for survival, two-tailed Mann–Whitney U test for GVHD Score, data are pooled from two experiments). e PCoA of distances between communities of the fecal microbiota of left; eight allo-B6 WT versus eight ABX allo-B6 WT, P = 0.022 by AMOVA, center; eight allo-GPCR43^−/− versus eight ABX allo-GPCR43^−/−, P = 0.033 by AMOVA, right; four ABX allo-B6 WT versus eight ABX allo-GPCR43^−/−, P = 0.022 by AMOVA. f Survival after BMT for WT B6 (left) or Gpr43^−/− (right) recipients treated with antibiotics (n = 3 each syngeneic, n = 12 each allogeneic WT B6, n = 14 each allogeneic Gpr43^−/−, log-rank test for survival). Data are representative of two experiments. *P < 0.05, ***P < 0.001, Bars and error bars show the mean ± s.e.m.